Healthcare Costs of Long-Acting Insulin Analogs vs NPH Insulin in Type 2 Diabetes Patients Using a Basal Regimen in Denmark

被引：0

|

作者：

Gundgaard, Jens

Aagren, Mark

Thomsen, Trine L.

机构：

来源：

DIABETES | 2009年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A316 / A317

页数：2

相关论文

共 50 条

[1] Healthcare Costs of Long-Acting Insulin Analogs vs NPH in Patients with Type 2 Diabetes Using a Basal-Bolus Regimen in Denmark
Gundgaard, Jens
Christensen, Torsten
Thomsen, Trine Lyager
DIABETES, 2010, 59 : A347 - A347
[2] Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen
Gundgaard, Jens
Christensen, Torsten E.
Thomsen, Trine Lyager
PRIMARY CARE DIABETES, 2010, 4 (03) : 165 - 172
[3] THE HEALTH CARE COSTS OF LONG-ACTING INSULIN ANALOGS COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES USING A BASAL REGIMEN: A DANISH PERSPECTIVE
Gundgaard, J.
Christensen, T.
Thomsen, T. L.
VALUE IN HEALTH, 2010, 13 (03) : A57 - A57
[4] Healthcare costs of long-acting insulin analogues compared with NPH insulin in patients using a basal regimen: a Danish perspective
Gundgaard, J.
Aagren, M.
Thomsen, T. L.
DIABETOLOGIA, 2009, 52 : S94 - S95
[5] Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
Chang, Chia-Hsuin
Chuang, Lee-Ming
JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (04): : 728 - 730
[6] Healthcare costs of fast-acting insulin analogues vs. short-acting human insulin in combination with long-acting insulin analogues for Danish patients with type 2 diabetes
Gundgaard, J.
Christensen, T.
Thomsen, T.
DIABETOLOGIA, 2010, 53
[7] THE UTILISATION AND SWITCHING RATES OF NEUTRAL PROTAMINE HAGEDORN (NPH) INSULIN AND LONG-ACTING INSULIN ANALOGS IN PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM
Brunetti, V. C.
Yu, O. H. Y.
Platt, R. W.
Filion, K. B.
VALUE IN HEALTH, 2020, 23 : S512 - S512
[8] Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Horvath, K.
Jeitler, K.
Berghold, A.
Ebrahim, S. H.
Gratzer, T. W.
Plank, J.
Kaiser, T.
Pieber, T. R.
Siebenhofer, A.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (02):
[9] A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK
Idris, Iskandar
Gordon, Jason
Tilling, Carl
Vora, Jiten
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 273 - 282
[10] The utilization of long-acting insulin analogues and intermediate-acting NPH insulin among patients with type 2 diabetes in the United Kingdom
Brunetti, Vanessa C.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 404 - 404

← 1 2 3 4 5 →